Immunotherapy Clinical Trials
Here are the 6 most popular medical studies for immunotherapy
IDO1 Inhibitor
Combination Immunotherapy for Pancreatic Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial will enroll patients with metastatic pancreatic cancer who have progressed on prior chemotherapy. Patients will receive a combination of epacadostat, pembrolizumab, and either cyclophosphamide/GVAX pancreas vaccine or CRS-207. The primary objectives of the study are to determine the recommended dose of epacadostat and to assess the survival of patients in both treatment groups.
Cancer Vaccine
ESR1 Peptide Vaccine for Breast Cancer
Recruiting1 awardPhase 1
Durham, North Carolina
This trial is testing a cancer vaccine made of peptides that stimulate the immune system, combined with an adjuvant and GM-CSF. The primary objective is to evaluate safety, and the secondary objective is to evaluate the ability of the vaccine to create an immune response.
Monoclonal Antibodies
TAB004 + Toripalimab for Advanced Malignancies
Recruiting1 awardPhase 1
Tucson, Arizona
This trial is studying a drug called TAB004 given alone or with another drug called toripalimab to see if it is safe and tolerable in treating subjects with selected advanced solid malignancies.
Immunotherapy
Modern Immunotherapy for Bladder Cancer
Recruiting1 awardPhase 1 & 2
Indianapolis, Indiana
This trial is for a treatment for bladder cancer. It will test different combinations of drugs, some with BCG and some without. If the side effects from a certain combination are too severe, that combination will not be used.
Popular filter options for immunotherapy trials
Phase 3 Clinical Trials
View 89 phase 3 medical studies.
Immunotherapy
BCG + N-803 for Bladder Cancer
Recruiting1 awardPhase 2 & 3
Los Angeles, California
This trial is testing a new drug, N-803, for people with bladder cancer that has not responded to BCG treatment. Patients will receive the new drug through a urinary catheter weekly for 6 weeks, followed by maintenance treatment every 3 or 6 weeks for up to 3 years.
Dendritic cell immunotherapy
Dendritic Cell Therapy for Glioblastoma
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing a new therapy, DCVax-L, for patients with newly diagnosed Glioblastoma (GBM) who are scheduled for surgery. The patients will receive the standard of care, including radiation and Temodar therapy, and then will be randomly assigned to also receive either DCVax-L or a placebo. All patients will have the option to receive DCVax-L after their disease progresses.
Immunoglobulin
Anti-Coronavirus Immunoglobulin for COVID-19
Recruiting1 awardPhase 3
Washington, District of Columbia
This trial is for people with recently diagnosed SARS-CoV-2 infection who do not require hospitalization. The goal is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo.
Clinical Trials With No Placebo
View 89 medical studies that do not have a placebo group.
Immunotherapy
Trastuzumab + Alpha-TEA for HER2+ Metastatic Breast Cancer
Recruiting1 awardPhase 1
Seattle, Washington
This trial is testing the effects of a new drug, alpha-TEA, when given with the existing drug trastuzumab, for the treatment of HER2+ breast cancer that has stopped responding to other treatments and has spread to other parts of the body.
Cancer Vaccine
pTVG-HP + pTVG-AR + Pembrolizumab for Prostate Cancer
Recruiting1 awardPhase 2
Saint Louis, Missouri
This trial will evaluate the use of one versus two DNA vaccines to treat prostate cancer that has spread and is no longer responding to hormone therapy. The hypothesis is that delivering two vaccines with a drug that blocks PD-1 will increase the percentage of patients experiencing an anti-tumor effect.
Cytokine
THOR-707 Combination Therapy for Cancer
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing the safety and effectiveness of a new cancer drug, THOR-707, either alone or in combination with other drugs. The goal is to find the best dose of THOR-707 with the least side effects. Secondary goals are to see if THOR-707 can shrink tumors, and how long any shrinkage lasts.
Virus Therapy
Gene Mediated Cytotoxic Immunotherapy for Lung Cancer
Recruiting1 awardPhase 1
Philadelphia, Pennsylvania
This trial is testing a new cancer treatment, which uses a person's own immune cells to fight their cancer. The goal is to see if it is safe and if it causes any changes in the immune system.
View More Immunotherapy Trials
See another 70 many medical studies focused on immunotherapy.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.